Metabolic Tumor Volume Complements Metrics in RECIL and Lugano Criteria in Response Assessment in Multiple Relapsed Hodgkin Lymphoma (EANM 2026) - Sep 29, 2026 - Abstract #EP-0540; "Patients received radiotherapy (RT) to one target lesion plus nivolumab... MTV4.0 may serve as a complementary metric in addition to Lugano and RECIL CT-criteria for assessing therapy response in relapsed HL. It allows semiautomated measurement, particularly in patients with PR and anatomically difficult to assess lesions. Since morphological decline often occurs more slowly, therapeutic success can be detected earlier using MTV4.0."
IO biomarker • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology
|
|
J. Weindler 1; P. Bröckelmann 2; C. Baues 3; J. Rosenbrock 4; K. Roth 1; C. Kobe 1
|